NOVATO, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced today a program update for its lead investigational compound, RP103 for the potential treatment of nephropathic cystinosis. RP103 is Raptor's proprietary, enteric-coated, microbead delayed-release oral formulation of cysteamine bitartrate designed to potentially reduce dosing frequency and reduce gastrointestinal side effects associated with the currently approved immediate-release cysteamine bitartrate.
